Targeting NLRP3 inflammasome of microglia is another strategy against AD and AD-related inflammatory responses, a small molecule NLRP3 inhibitor such as JC-124, and MCC950 has been discovered which vigorously pro-inflammatory cytokines, chemokines, and ROS in AD however, along with more comprehensive evaluations of the outcomes, could produce delightfully unexpected results (Yin et al., 2018; Kelley et al., 2019; Zhang et al., 2021; Sharma et al., 2023). Here, NLRP3 is linked to Alzheimer disease.